Therefore, differential DNA methylation profiles in prostate tumors with PTEN loss may help to better understand the mechanisms that drive cancer progression in the absence of PTEN. To gain insights on this issue, we examined the association of PTEN loss with PCa recurrence in a cohort of patients diagnosed with clinically localized disease, and used methylome data from the same cohort to profile tumors with and without PTEN loss. This evidence concerns the gene PTEN and cancer.